Literature DB >> 12942374

Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy.

Donald P Kotler1, Gabriel Ionescu, Julia A Johnson, Yori Inada, Qing He, Ellen S Engelson, Jeanine B Albu.   

Abstract

We studied aspects of metabolism in subcutaneous adipose tissue (SAT) in 40 human immunodeficiency virus (HIV)-infected subjects with and without lipodystrophy and in healthy control subjects. HIV-infected subjects without lipodystrophy had less SAT and visceral adipose tissue (VAT). Glycerol release was higher in both HIV-infected groups, especially those without fat redistribution. Tumor necrosis factor (TNF) release from SAT and serum soluble TNF receptor 2 concentrations were significantly higher in HIV-infected individuals with lipodystrophy. The absolute production of acylation-stimulating protein (ASP) and the percentage conversion of the complement protein to ASP were significantly lower in HIV-infected subjects with lipodystrophy. Further studies are needed to dissect the factors that mediate lipoatrophy in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942374     DOI: 10.1086/375891

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Intermuscular and subcutaneous adipose tissue distributions differ in HIV+ versus HIV-men and women.

Authors:  G B Dodell; D P Kotler; E S Engelson; G Ionescu; Y Gimelshteyn; A Pollack; D Gallagher; L Berglund; J B Albu
Journal:  Int J Body Compos Res       Date:  2009

2.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

3.  Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

Authors:  Stéphanie Leroyer; Camille Vatier; Sarah Kadiri; Joëlle Quette; Charles Chapron; Jacqueline Capeau; Bénédicte Antoine
Journal:  J Lipid Res       Date:  2010-11-10       Impact factor: 5.922

Review 4.  The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.

Authors:  Katherine Samaras
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

5.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

6.  Obesity and immune cell counts in women.

Authors:  Julie Womack; Phyllis C Tien; Joseph Feldman; Ja Hyun Shin; Kristopher Fennie; Kathryn Anastos; Mardge H Cohen; Melanie C Bacon; Howard Minkoff
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

7.  The role of HIV and monocytes/macrophages in adipose tissue biology.

Authors:  Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

8.  Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

Authors:  Allison Martin; Janaki Amin; Sean Emery; David Baker; Andrew Carr; David A Cooper; Mark Bloch
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

9.  HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms.

Authors:  Kenneth Lichtenstein; Ashok Balasubramanyam; Rajagopal Sekhar; Eric Freedland
Journal:  AIDS Res Ther       Date:  2007-06-27       Impact factor: 2.250

10.  HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Authors:  Allison Martin; Cecilia L Moore; Patrick W G Mallon; Jennifer F Hoy; Sean Emery; Waldo H Belloso; Praphan Phanuphak; Samuel Ferret; David A Cooper; Mark A Boyd
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.